1. INTRODUCTION {#acm212355-sec-0001}
===============

In the past decade, stereotactic radiation therapy has been increasingly used in the management of both intracranial (stereotactic radiosurgery, SRS) and extracranial tumors (stereotactic body radiation therapy, SBRT). This technique is able to precisely deliver very high doses to the tumors while sparing the adjacent normal tissues in just a few fractions, and has been proven to provide superior or comparable treatment outcomes and is cost‐effective relative to alternative conventional techniques.[1](#acm212355-bib-0001){ref-type="ref"}, [2](#acm212355-bib-0002){ref-type="ref"}, [3](#acm212355-bib-0003){ref-type="ref"}, [4](#acm212355-bib-0004){ref-type="ref"}, [5](#acm212355-bib-0005){ref-type="ref"}, [6](#acm212355-bib-0006){ref-type="ref"}, [7](#acm212355-bib-0007){ref-type="ref"}, [8](#acm212355-bib-0008){ref-type="ref"}, [9](#acm212355-bib-0009){ref-type="ref"}, [10](#acm212355-bib-0010){ref-type="ref"}

Several delivery options have been implemented in Linac‐based stereotactic treatments, including noncoplanar three‐dimensional conformal radiation therapy (3D‐CRT), dynamic conformal arcs (DCA), intensity modulated radiation therapy (IMRT, including sliding window and step‐and‐shoot techniques), and volumetric modulated arc therapy (VMAT). Recently DCA and VMAT have become popular due to their delivery efficiency compared to 3D‐CRT and IMRT. For DCA treatment, the multileaf collimator (MLC) is shaped to conform to the planning target volume (PTV) based on the beam\'s eye view (BEV) as the gantry rotates around the patient. The gantry speed and dose rate remain constant during the DCA delivery.

Volumetric modulated arc therapy was first introduced and implemented into the clinic as a novel radiation delivery technique[11](#acm212355-bib-0011){ref-type="ref"}, [12](#acm212355-bib-0012){ref-type="ref"} that was a variation on static field IMRT. Unlike DCA, VMAT plans are generated by an inverse planning algorithm, which allows modulation of the gantry rotation speed, dose rate, and also the position and speed of MLC. It is recommended that VMAT plans always be validated with a patient‐specific QA measurement before treatment. Compared to VMAT, DCA techniques offer advantages in terms of reduced multileaf collimator (MLC) motion complexity, positioning error, and delivery efficiency, thus DCA may be the desired delivery modality from a technical treatment delivery viewpoint. However, VMAT may be favored due to its increased ability for dose shaping when certain critical organs sparing becomes important.

The photon optimization (PO) algorithm was recently released by Varian Medical System (Palo Alto, CA, USA) to improve IMRT and VMAT optimizations in Eclipse treatment planning system (TPS) version 13.5. The PO algorithm combines the dose--volume optimizer (DVO) used for static field IMRT and the progressive resolution optimizer (PRO) used for VMAT plans from the previous Eclipse version. Both PRO and PO algorithms create VMAT plans based on dose--volume objectives, and generate a sequence of control points, which define MLC leaf positions and MU/degree as a function of gantry angle. For both PRO and PO algorithms, the initial conditions are defined using control points to represent each VMAT field; a multiresolution approach and an objective function (the sum of the dose--volume and user‐defined objectives) are used to optimize the plan. The multiresolution dose calculation (MRDC) algorithm is used to increase the dose calculation accuracy with progressive dose calculation segments using a point cloud‐based model.[13](#acm212355-bib-0013){ref-type="ref"} The optimization process goes through four multiresolution level, in which number of dose calculation segments increase progressively at each level. The number of control points keeps unchanged during the whole optimization process.

The main difference of the PO algorithm from the PRO algorithm is that instead of using a point cloud mode for defining structures in PRO, the PO algorithm implements a new structure model, where structures, DVH calculations, and dose sampling are defined spatially using a single matrix over the image. Fixed values (1.25 mm, 2.5 mm, or 5 mm) are used for the voxel resolution of the matrix. This resolution defines the planar X and Y resolution in the slices, and the Z resolution orthogonal to the slices is a function of chosen resolution and the slice spacing. This matrix defines the locations of the structures and the sampling of the dose, and it replaces the previously used point clouds in PRO algorithm. The DVH for the structures is evaluated using volume weights defined for each voxel. A workflow change has been made for the PO algorithm in the latest version of Eclipse TPS (version 15.1), namely, the users are allowed to control the field aperture shape (DCA in this study) before the VMAT optimization. This workflow was not supported in the previous Eclipse version for PO algorithm due to constraints of the field types being used for the optimizer. Initializing the VMAT inverse plan based on a DCA‐like formation of MLC apertures could potentially reduce the MLC modulation in the treatment planning process. Figure [1](#acm212355-fig-0001){ref-type="fig"} shows the comparison between the PRO and PO algorithms. The purpose of this study is to compare the PO algorithm (version 15.1) with its predecessor, the PRO algorithm (version 13.6), in terms of MLC modulation reduction while preserving plan quality for both lung SBRT and brain SRS treatments.

![Comparisons of PRO and PO algorithms.](ACM2-19-155-g001){#acm212355-fig-0001}

2. METHODS {#acm212355-sec-0002}
==========

This retrospective analysis included 20 lung SBRT patients (10 received 54 Gy in 3 fractions and 10 received 50 Gy in 5 fractions) and 10 SRS patients (25 Gy in 5 fractions). All planning computer tomography (CT) images were acquired on a Philips Brilliance Big Bore CT scanner (Philips, Cleveland, OH, USA) with fields of view large enough to cover the patient and immobilization devices, the slice thickness was 2 mm for lung SBRT patients and 1 mm for SRS patients. All patients were treated on a Varian TrueBeam STx platform.

All lung SBRT patients were immobilized using a customized full‐body length vacuum bag (Bodyfix, Medical Intelligence Inc) for simulation and subsequent treatments. Paddle‐based abdominal compression was applied to restrict the tumor motion within 1.5 cm if needed. All patients underwent a free breathing and a 10‐phase four‐dimensional CT (4DCT) scan. The respiratory motion was captured with a Philips bellows system placed around the patient abdomen. An internal target volume (ITV) was created based on the maximum intensity projection (MIP) of 4DCT image, and the PTV was created by a 5 mm uniform expansion of the ITV. The original clinical plans used for treatment were created on the free‐breathing CT and involved two 6 MV flattering filter free (6X‐FFF) beams. Each clinical plan was normalized such that at least 95% of the PTV received the prescription dose, and more than 99% of the PTV received at least 90% of the prescription dose. The maximum point dose and dose--volume constraints of several critical organs are listed in Table [1](#acm212355-tbl-0001){ref-type="table"} for both 54 and 50 Gy protocols.[14](#acm212355-bib-0014){ref-type="ref"}, [15](#acm212355-bib-0015){ref-type="ref"}, [16](#acm212355-bib-0016){ref-type="ref"}

###### 

Lung SBRT planning acceptance objectives for critical organs

  -----------------------------------------------------------
  Serial tissue   Volume       54 Gy   50 Gy           
  --------------- ------------ ------- ------- ------- ------
  Spinal cord     \<0.25 cc\           18      22.5\   30
                  \<0.5 cc                     13.5    

  Lungs‐ITV       \<15%        20              20      

  Esophagus       \<5 cc       17.7    25.2    19.5    35

  Aorta           \<10 cc      39      45      47      53

  Trachea         \<4 cc       15      30      16.5    40

  Skin            \<10 cc      30      33      36.5    39.5

  Chest wall      \<30 cc      30              30      
  -----------------------------------------------------------
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All SRS patients were immobilized in BrainLab SRS masks (BrainLab AG, Feldkirchen, Germany) and received IV contrast prior to the CT scan when possible. All patients also underwent MR scans, which were registered with the planning CT to define the gross tumor volume (GTV). The GTV was expanded by 1 mm margin uniformly to form the PTV. MR scans were acquired on a GE Signa EXCITE 3.0T MRI scanner (GE Healthcare, Waukesha, WI, USA) with 1 mm slice thickness and a field of view large enough to include the entire surface of the patient. Postcontrast T1‐weighted axial scans were used for all cases. 6X‐FFF beams with 3--4 table kicks were used for the original clinical VMAT plans, and at least 99% of PTV and 100% GTV coverages were enforced. The maximum point dose and dose--volume constraints for critical structures followed the guidelines of AAPM TG‐101.[14](#acm212355-bib-0014){ref-type="ref"}

All the clinical plans were optimized in Eclipse version 13.6 with the PRO algorithm, which is based on dose--volume objectives. All plans were reoptimized with the new PO algorithm in Eclipse version 15, which offers a VMAT optimization based on an initial DCA plan as described above. The PO algorithm determines the optimal field shape and intensity by interactively conforming the dose distribution to the desired objectives until an optimum solution is reached. In the new PO algorithm, DCA was first used to conform to the target and followed by VMAT inverse planning to achieve the desired dose distribution. The DCA beams were automatically fit with 3--4 mm margin around the PTV, and the same beam configurations (gantry, collimator and table angles) were used in the re‐plan. In order to isolate the variation due to the planning optimization algorithm, the same planning objectives, constraints, and weightings for the target and critical organs were used for both the PRO and PO plans. The settings were also retained for normal tissue optimization (NTO) and the MU objectives.

PTV coverage was forced to be identical for the same patient in order to have a comparison between the PRO and PO algorithms (at least 95% for lung SBRT and 99% for SRS patients). For lung SBRT treatments, selected dose--volume parameters were compared for the PRO and PO plans, including the conformity index (*CI* ~50~, volume receiving 50% of prescription dose/PTV volume) for the PTV, *V* ~20~ (lung volume receives 20 Gy) for lungs, *V* ~30 Gy~ for chest wall, and *D* ~0.035 cc~ (dose to the 0.035 cc of the volume, a representative of maximum dose) for all other critical organs, such as spinal cord, aorta, and trachea. For brain SRS treatments, plan quality was evaluated based on the conformity index (*CI* ~100~) for the PTV and normal volumes encompassed by the 12 and 6 Gy isodose lines (*V* ~12~ and *V* ~6~).

Treatment plan complexity was assessed by using the modulation complexity score (MCS) and average open aperture per control point (AA). The MCS was originally defined by McNiven to evaluate the plan complexity and deliverability for step‐and‐shoot IMRT plans,[17](#acm212355-bib-0017){ref-type="ref"} and then modified by Masi in order to apply for VMAT plans (considering control points of the arc instead of segments).[18](#acm212355-bib-0018){ref-type="ref"} The plan complexity analysis (MCS and AA) was implemented as a plug‐in script to the Varian Eclipse planning system. Higher MCS and AA values mean less plan complexity, and easier plan deliverability.

Agreement of the planning and delivered doses was assessed by studying the patient‐specific QA results. Patient‐specific QA was performed with ArcCHECK (Sun Nuclear) and gamma passing rates were compared between the PRO and PO plans. The criteria for gamma analysis were 3%/3 mm and 2%/2 mm for SBRT plans, and 5%/1 mm and 3%/1 mm for SRS plans with 10% threshold. The Mann--Whitney U test was used to evaluate the differences between the two groups of plans for MCS, total MUs used, gamma passing rate, and dosimetric parameters for critical structures.

All work was carried with the approval of the institutional review board under protocol number 1767.

3. RESULTS {#acm212355-sec-0003}
==========

The average volume of the PTV for SBRT patients was 34.1 ± 12.5 cc (range from 10.1 to 54.2 cc) and 30.8 ± 18.1 cc (range from 9.7 to 59.5 cc) for 54 and 50 Gy treatments, respectively. The average volume of the PTV was 10.1 ± 10.3 cc (range from 0.9 to 31.4 cc) for SRS patients. Table [2](#acm212355-tbl-0002){ref-type="table"} lists the distribution of the tumor locations and target coverage for the group of the patients included in this analysis.

###### 

Patient characteristics and PTV coverage

       Lung SBRT   Brain SRS                                                
  ---- ----------- ----------- ----- ------ ----- ----- ------ ------------ -------
  1    19.6        LUL         97%   19.1   LLL   97%   6.0    Pituitary    99.7%
  2    54.2        LUL         96%   35.3   RUL   97%   5.2    Pituitary    99.3%
  3    34.2        RML         97%   47.6   RLL   95%   31.4   Pituitary    99.0%
  4    36.9        LUL         97%   59.5   RLL   97%   9.1    Orbit        99.0%
  5    37.2        RUL         97%   32.5   LUL   95%   5.5    Frontal      99.5%
  6    31.0        LUL         98%   9.7    LUL   95%   6.6    Parietal     99.0%
  7    27.3        LUL         97%   13.2   RUL   95%   4.5    Frontal      99.5%
  8    40.3        LLL         96%   54.9   RML   95%   27.0   Skull base   99.5%
  9    20.2        LLL         97%   20.9   RLL   97%   4.7    Pituitary    99.5%
  10   10.1        RLL         97%   15.3   LUL   97%   0.9    Pituitary    99.0%

LUL, left upper lobe; LLL, left lower lube; RUL, right upper lobe; RLL, right lower lube; RML, right middle lobe.
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Table [3](#acm212355-tbl-0003){ref-type="table"} listed the average and standard deviations of MCS, AA, total MUs, and gamma passing rates of PRO and PO plans for both SBRT and SRS treatments. Figure [2](#acm212355-fig-0002){ref-type="fig"} compares the calculated MCS and AA values for both PRO and PO plans for each individual patient. Compared to the PRO plans, MCS and AA values are larger for the PO plans, indicating PO plans have reduced plan complexity. Figure [3](#acm212355-fig-0003){ref-type="fig"} compares the gamma passing rates between the PRO and PO plans for SBRT and SRS treatments with different passing criteria. Better agreement between the planned and delivered doses was found for the PO plans for all patients included in this study.

###### 

Comparisons of average MCS, AA, total MUs, and gamma passing rates between the PRO and PO plans for SBRT and SRS treatments

  SBRT           SRS                                                                                  
  -------------- ------------- ------------- ------------- ------------- -------------- ------------- -------------
  MCS            0.38 ± 0.08   0.51 ± 0.04   0.34 ± 0.08   0.51 ± 0.08   MCS            0.28 ± 0.07   0.38 ± 0.05
  AA             927 ± 371     1184 ± 361    849 ± 375     1254 ± 469    AA             379 ± 143     507 ± 184
  Total MU       5723 ± 1045   4151 ± 475    3388 ± 574    2241 ± 453    Total MU       1820 ± 600    1304 ± 473
  *γ*(3%/3 mm)   97.9 ± 1.5    99.2 ± 1.2    96.1 ± 2.4    99.1 ± 1.0    *γ*(5%/1 mm)   96.1 ± 3.4    98.4 ± 2.0
  *γ*(2%/2 mm)   94.8 ± 2.8    97.7 ± 1.2    91.1 ± 3.2    96.0 ± 2.2    *γ*(3%/1 mm)   90.6 ± 5.1    95.7 ± 4.6

John Wiley & Sons, Ltd

![Comparisons of MCS and AA between the PRO‐ and PO plans for SBRT and SRS treatments. (a) MCS for 54 Gy SBRT; (b) AA for 54 Gy SBRT; (c) MCS for 50 Gy SBRT; (d) AA for 50 Gy SBRT; (e) MCS for SRS; (f) AA for SRS.](ACM2-19-155-g002){#acm212355-fig-0002}

![Comparisons of gamma passing rates between the PRO and PO plans for SBRT and SRS treatments. (a) 3%/3 mm for 54 Gy SBRT; (b) 2%/2 mm for 54 Gy SBRT; (c) 3%/3 mm for 50 Gy SBRT; (d) 2%/2 mm for 50 Gy SBRT; (e) 5%/1 mm for SRS; (f) 3%/1 mm for SRS.](ACM2-19-155-g003){#acm212355-fig-0003}

Mann--Whitney U tests were performed between the two algorithm groups, and the resulting *P*‐values are listed in Table [4](#acm212355-tbl-0004){ref-type="table"} for both SBRT and SRS treatments. No statistically significant differences between the two algorithms were found for *CI* ~50~ or doses to critical structures for SBRT patients (*P \>*\> 0.05 from the Mann--Whitney U test). The same conclusion can be drawn with regard to the differences between two algorithms for *CI* ~100~ and the ratio of *V* ~12~, *V* ~6~, and *V* ~*3*~ for SRS patients. This indicates the PRO and PO algorithms produce very similar plan quality for the stereotactic treatments.

###### 

*P*‐values from the Mann--Whitney U test for the PRO‐ and PO plans

                          SBRT    SRS                     
  ----------------------- ------- ------- --------------- -------
  MCS                     0.001   0.001   MCS             0.005
  Total MU                0.001   0.001   Total MU        0.024
  *γ* (3%/3 mm)           0.008   0.004   *γ* (5%/1 mm)   0.097
  *γ* (2%/2 mm)           0.005   0.005   *γ* (3%/1 mm)   0.026
  *CI* ~50~               0.596   0.289   *CI* ~100~      0.364
  *V* ~20 Gy~ (Lung)      0.881   0.912   *V* ~12~        0.968
  *D* ~max~ (Eso)         0.795   0.912   *V* ~6~         0.728
  *D* ~max~ (Aorta)       0.818   0.340   *V* ~3~         0.795
  *D* ~max~ (trach)       0.968   1.000                   
  *D* ~max~ (Skin)        0.968   0.968                   
  *V* ~30~ (Chest wall)   0.728   0.849                   
  *D* ~max~ (Cord)        0.912   1.000                   
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As can be seen from Table [4](#acm212355-tbl-0004){ref-type="table"}, statistically significant improvements in the MLC modulation (larger MCS value), delivery efficiency (reduced total MUs), and better agreement between the planned and delivered doses (improved gamma passing rate) were found for the new PO method. The MCS showed a strong correlation with gamma passing rate and an inverse correlation with the total MUs used in the plan.

4. DISCUSSION {#acm212355-sec-0004}
=============

Currently, DCA and VMAT are two of the most frequently used techniques in stereotactic treatment planning. DCA may be considered desirable due to advantages over VMAT including minimizing the MLC motion, position error, and delivery efficiency, etc. However, in some cases, VMAT may be able to provide more conformal dose distributions and better sparing of critical organs due to its ability to modulate intensity, especially for cases where the doses to the critical structures become a concern. Varian Medical Systems has launched the PO algorithm to combine the previous DVO and PRO algorithms as of Eclipse version 13.5. The PO algorithm further improved in version 15 by allowing the user to start the VMAT optimization from DCA plans. The main difference of the PO algorithm from the earlier PRO algorithm is that PO algorithm uses a new method to model the structure, which allows the user to optimize the VMAT plans directly from DCA beams. The purpose of this study is to compare the new photon optimization algorithm using a DCA initialization with its predecessor, the progressive resolution optimizer, in terms of MLC modulation, delivery efficiency, and agreement between the planned and delivered doses for both lung SBRT and brain SRS patients.

As shown in Table [4](#acm212355-tbl-0004){ref-type="table"}, no statistically significant differences (*P* \<\< 0.05 from Mann--Whitney U test) were found for any of the dosimetric parameters between the PO and PRO algorithms (the target coverages were forced to be identical for both algorithms for a similar comparison), indicating both algorithms had comparable plan quality. Compared to the PRO plans, statistical significant improvements (*P *\<* *0.05) were found for the PO plans in terms of MLC modulation (MCS and AA), total MUs used, and the gamma passing rate for the patient‐specific QA.

Two metrics, MCS (between 0 and 1) and AA, were used to evaluate the overall plan complexity for both PRO and PO plans. The MCS incorporates the leaf sequence variability and the aperture area variability into the calculation. Compared to the PRO plans, an average increase in MCS values for PO plans of 0.15 (from 0.36 to 0.51) and 0.10 (from 0.28 to 0.38) were found for SBRT and SRS, and an average increase in AA values of 331 (from 888 to 1219) and 128 (from 379 to 507). This indicated PO plans have reduced plan complexity and easier plan deliverability compare to PRO plans.

PO plans have significantly smaller total MUs used than the PRO plans (total MU reduction of 29.8% for SBRT and 28.3% for SRS). Less MUs used indicating increased plan delivery efficiency, which yields reduced intrafraction motion, and also increased patient comfort. Less beam modulation of the PO plans gives less head leakage and less collimator scattering, which could have an impact on the effort to decrease out‐of‐field dose and secondary cancers.[19](#acm212355-bib-0019){ref-type="ref"}

In our clinical practice, the guideline for passing the patient‐specific QA is *γ *\> 95% at 3%/3 mm for SBRT and 5%/1 mm for SRS treatments, respectively. Better agreement between the planned and delivered doses (*γ* increased from 97.0% to 99.2% at 3%/3 mm criteria for SBRT plans and from 96.1% to 98.4% at 5%/1 mm criteria for SRS plans) were found for the PO plans. Results from tighter criteria (2%/2 mm for SBRT and 3%/1 mm for SRS) were also included in our analysis to gain more insight of the deviation of planned and delivered dose. Compared to the PRO plans, *γ* of PO plans increased from 93.0% to 96.8% at 2%/2 mm criteria for SBRT plans and from 90.6% to 95.7% at 3%/1 mm criteria for SRS plans. Better QA results from PO plans can be attributed to reduced plan modulation (MCS and AA) for the new PO algorithm, which is consistent with previous a finding.[18](#acm212355-bib-0018){ref-type="ref"} Figure [4](#acm212355-fig-0004){ref-type="fig"} compares the MLC openings for five randomly selected control points between the PO and PRO plans for a representative SRS patient. We want to point out that the MLC openings for other control points have similar behaviors like those showed in the figure. One thing we noticed was the new PO algorithm reduced the small MLC opening significantly when compared to the PRO plans, this can be indicated by the increase in AA values. Small MLC opening in the VMAT plans may lead to dosimetric uncertainty due to the small field dosimetry uncertainty in the beam model. Less MUs and larger MLC openings could lead to better agreement between the planned and delivered doses in the PO algorithm, as observed by Vanetti and Giorgia.[20](#acm212355-bib-0020){ref-type="ref"}, [21](#acm212355-bib-0021){ref-type="ref"}

![Comparisons of selective MLC openings between the PO and PRO algorithms for a representative SRS treatment. (a) PO algorithm; (b) PRO algorithm.](ACM2-19-155-g004){#acm212355-fig-0004}

5. CONCLUSION {#acm212355-sec-0005}
=============

The new PO algorithm offers comparable dosimetry to the PRO algorithm. The new PO algorithm has better gamma passing rate, indicating better agreement between the planned and delivered doses. Furthermore, the new PO algorithm has much less MLC complexity and total MUs, thereby improving the delivery efficiency and QA results. This could potentially reduce the uncertainty when considering patient interfraction motion during the course of treatment.
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DEFINITION OF MODULATION METRICS (MCS) AND AVERAGE APERTURE (AA) {#acm212355-sec-0007}
================================================================

The MSC for VMAT plans was originally defined by McNiven for step‐and‐shoot IMRT plans,[17](#acm212355-bib-0017){ref-type="ref"} and then modified by Masi in order to apply for VMAT plans.[18](#acm212355-bib-0018){ref-type="ref"} The LSV is defined based on the difference in position for adjacent MLC leaves in the same bank for each control point (CP). The positional variations are considered relative to the maximum MLC variation per bank for each CP. The maximum variation per CP is defined as: $$\begin{array}{r}
{Pos_{\mathit{\max}}\left( \mathit{CP} \right) = {\langle{\text{max}\left( {pos_{n \in N}} \right) - \text{min}\left( {pos_{n \in N}} \right)}\rangle}_{leaf\, bank},} \\
\end{array}$$ $$\begin{array}{cl}
{LSV_{\mathit{CP}} =} & \left( \frac{\sum_{n = 1}^{N - 1}\left( {pos_{\mathit{\max}} - \left| {pos_{n} - pos_{n + 1}} \right|} \right)}{\left( {N - 1} \right) \times pos_{\mathit{\max}}} \right)_{left\, bank} \\
 & {\times {\left( \frac{\sum_{n = 1}^{N - 1}\left( {pos_{\mathit{\max}} - \left| {pos_{n} - pos_{n + 1}} \right|} \right)}{\left( {N - 1} \right) \times pos_{\mathit{\max}}} \right)_{right\, bank},}} \\
\end{array}$$where *N* is the number of moving leaves and *pos* ~*n*~ is the position of leaf *n*.

The AAV is based on the area defined by opposing MLC leaves in a CP normalized to the maximum area in the arc, which is defined by the maximum apertures for all leaf pairs over all CPs in the arc$$\begin{array}{r}
{AAV_{\mathit{CP}} = \frac{\sum_{a = 1}^{A}\left( {{\langle{pos_{a}}\rangle}_{left\, bank} - {\langle{pos_{a}}\rangle}_{right\, bank}} \right)}{\sum_{a = 1}^{A}\left( {{\langle{\text{max}(pos_{a})}\rangle}_{left\, bank \in arc} - {\langle{\text{max}(pos_{a})}\rangle}_{right\, bank \in arc}} \right)},} \\
\end{array}$$where *A* is the number of moving leaves in the arc.

The MLCs are continuously moving between CP while MU are being delivered, so MCS considers the mean values of *LSV* ~*CP*~ and *AAV* ~*CP*~ between adjacent CPs. This product is weighted by the percentage of total MU delivered between the adjacent CPs:$$MCS = \sum\limits_{i = 1}^{I - 1}\left\lbrack {\frac{(AAV_{CP_{i} +}AAV_{CP_{i + 1}})}{2} \times \frac{(LSV_{CP_{i} +}LSV_{CP_{i + 1}})}{2} \times \frac{MU_{CP_{i,i + 1}}}{MU_{\mathit{arc}}}} \right\rbrack,$$where I is the number of CP and MU~CPi,i+1~ are the MU delivered between two consecutive CPs.

The *AA* term is defined using the notation from above as$$AACP = \sum\limits_{a = 1}^{A}{({\langle{pos_{a}}\rangle}_{left\mspace{720mu} bank} - {\langle pos_{a}\rangle}_{right\mspace{720mu} bank})} \times w_{a}$$where *w* ~*a*~ is the width of leaf *a* $$AA_{\mathit{arc}} = \frac{\sum_{i = 1}^{I - 1}\left\lbrack {\frac{(AACP_{CP_{i} +}AACP_{CP_{i + 1}})}{2} \times \frac{MU_{CP_{i,i + 1}}}{MU_{\mathit{arc}}}} \right\rbrack}{I - 1}.$$
